Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Physician interpretation of genomic test results and treatment selection.

Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam F.

Cancer. 2018 Mar 1;124(5):966-972. doi: 10.1002/cncr.31112. Epub 2017 Nov 22.


"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource.

Kurnit KC, Bailey AM, Zeng J, Johnson AM, Shufean MA, Brusco L, Litzenburger BC, Sánchez NS, Khotskaya YB, Holla V, Simpson A, Mills GB, Mendelsohn J, Bernstam E, Shaw K, Meric-Bernstam F.

Cancer Res. 2017 Nov 1;77(21):e123-e126. doi: 10.1158/0008-5472.CAN-17-0341.


Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature.

Korphaisarn K, Loree JM, Nguyen V, Coulson R, Holla V, Litzenburger BC, Chen K, Mills GB, Maru DM, Meric-Bernstan F, Shaw KRM, Kopetz S.

Oncotarget. 2017 Jun 3;8(34):57882-57888. doi: 10.18632/oncotarget.18357. eCollection 2017 Aug 22.


ALK: a tyrosine kinase target for cancer therapy.

Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam F, Simon GR.

Cold Spring Harb Mol Case Stud. 2017 Jan;3(1):a001115. doi: 10.1101/mcs.a001115. Review.


Clinical Use of Precision Oncology Decision Support.

Johnson A, Khotskaya YB, Brusco L, Zeng J, Holla V, Bailey AM, Litzenburger BC, Sanchez N, Shufean MA, Piha-Paul S, Subbiah V, Hong D, Routbort M, Broaddus R, Mills Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00036. Epub 2017 Sep 13.


Proteomic Screening and Lasso Regression Reveal Differential Signaling in Insulin and Insulin-like Growth Factor I (IGF1) Pathways.

Erdem C, Nagle AM, Casa AJ, Litzenburger BC, Wang YF, Taylor DL, Lee AV, Lezon TR.

Mol Cell Proteomics. 2016 Sep;15(9):3045-57. doi: 10.1074/mcp.M115.057729. Epub 2016 Jun 30.


Automated identification of molecular effects of drugs (AIMED).

Fathiamini S, Johnson AM, Zeng J, Araya A, Holla V, Bailey AM, Litzenburger BC, Sanchez NS, Khotskaya Y, Xu H, Meric-Bernstam F, Bernstam EV, Cohen T.

J Am Med Inform Assoc. 2016 Jul;23(4):758-65. doi: 10.1093/jamia/ocw030. Epub 2016 Apr 23.


Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer.

Litzenburger BC, Brown PH.

Curr Breast Cancer Rep. 2014;6:96-109. Review.


Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists.

Schwittay A, Schumann C, Litzenburger BC, Schwenke K.

J Pain Palliat Care Pharmacother. 2013 Aug;27(3):225-34. doi: 10.3109/15360288.2013.816406. Epub 2013 Aug 19.


[Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].

Schwittay A, Schumann C, Litzenburger BC, Schwenke K.

MMW Fortschr Med. 2012 Oct 4;154 Suppl 3:85-93. German.


High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.

Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF, Lee AV.

Clin Cancer Res. 2011 Apr 15;17(8):2314-27. doi: 10.1158/1078-0432.CCR-10-1903. Epub 2010 Dec 22.


BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells.

Litzenburger BC, Kim HJ, Kuiatse I, Carboni JM, Attar RM, Gottardis MM, Fairchild CR, Lee AV.

Clin Cancer Res. 2009 Jan 1;15(1):226-37. doi: 10.1158/1078-0432.CCR-08-0801.


The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance.

Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X.

Front Biosci. 2008 May 1;13:3273-87. Review.


Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail.

Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, Lewis MT, Gottardis MM, Wong TW, Attar RM, Carboni JM, Lee AV.

Mol Cell Biol. 2007 Apr;27(8):3165-75. Epub 2007 Feb 12.

Supplemental Content

Loading ...
Support Center